

Secondary Metabolites and Biological Activities of *Talaromyces* sp. LGT-2, an Endophytic Fungus from *Tripterygium Wilfordii*

Qiu-Hong Zhao, Zhong-Duo Yang*, Zong-Mei Shu, Yong-Gang Wang and Ming-Gang Wang

School of Life Science and Engineering, Lanzhou University of Technology, Lanzhou.

Abstract

In the present study, eleven compounds (1-11) including nine alkaloids (1-9), one triterpenoid saponin (10) and one formamide (11) were isolated from *Talaromyces* sp. LGT-2, an endophytic fungus from *Tripterygium wilfordii*. Their structures were determined based on NMR and ESI-MS spectral data, as well as comparing with previous literature data. This is the first report of the isolation of alkaloids (1-9) from *Talaromyces* genus. In the next step, all compounds were screened for their anti-monoamine oxidase, anti-acetylcholinesterase, antibacterial and antitumor activities. Compound 11 showed moderate anti-monoamine oxidase activity with IC_{50} value of 61 μ M; compounds 3, 4, 8 showed weaker anti-acetylcholinesterase activity; compounds 1, 3, 4, 7, 8, 9 showed moderate antibacterial activities; compounds 7, 8, 9 showed cytotoxicity against B16 cancer cell line with inhibitory rate of 86%, 82%, 78%, respectively, at the concentration of 500 μ g/mL.

Keywords: endophytic fungus; secondary metabolites; monoamine oxidase inhibition; *Talaromyces*; *Tripterygium wilfordii*.

Introduction

Endophytic fungi have been proved to be a new source for natural compounds, literature reports that we can get secondary metabolites which have unique structure and wide range of biological activities, such as antitumor, antimicrobial and antituberculosis. Indeed, structural diversity of these metabolites make endophytic fungi a potential new lead for drug discovery and development (1, 2).

During our ongoing screening for new bioactive natural products from endophytes, we found the fermentation broth of *Talaromyces* sp. LGT-2 (GenBank Accession No. KF934203), an endophytic fungus inhabited in *Tripterygium wilfordii*, showed moderate monoamine oxidase

(MAO) inhibitory activity with IC_{50} value of 85 μ g/mL. Further chemical investigation resulted in the isolation of compounds 1-11 (Figure 1.). Anti-MAO activity, anti-acetylcholinesterase (anti-AChE), antitumor and antibacterial activities of compounds 1-11 were also evaluated in this study (Table 1.).

Experimental

Chemicals and Instrumentation: Column Chromatography (CC): was performed on silica gel (200–300 mesh) and Sephadex LH-20 gel. HPLC was performed on JASCO liquid chromatograph with C_{18} column. TLC: was carried out on silica gel GF254 by using various solvent systems. The structures of the compounds were determined based on their NMR and ESI-MS spectroscopy.

Fungus Material: Chinese medicine

* Corresponding author:

E-mail: yangzhongduo@126.com

Table 1. Anti-bacterial activity of monomer compounds (MIC, mg/mL).

Sample	<i>Escherichia coli</i>	<i>Pseudomonas Aeruginosa</i>	<i>Staphylococcus aureus</i>	<i>Bnfillus licheniformis</i>	<i>Streptococcus pneumoniae</i>
1	0.5	0.8	0.25	0.25	0.125
3	0.5	0.5	0.5	0.125	1
4	0.5	0.5	0.5	0.25	0.125
7	0.25	0.25	0.125	0.125	0.125
8	0.5	0.8	0.25	0.25	0.125
9	0.5	0.5	0.5	0.25	1

Tripterygium wilfordii was purchased from the local market in GanSu province of China in December 2013, and authenticated by Professor LinYang (School of Life Science and Engineering, Lan Zhou University Of Technology, Lan Zhou, China).

The strain LGT-2 was isolated from Chinese herb medicine *Tripterygium wilfordii* and was identified as *Talaromyces sp.* based on both morphology on PDA and analysis of the DNA sequences of the ITS1-5.8S-ITS2 ribosomal DNA gene region (GenBank Accession No. KF934203).

Extraction and Isolation: The fungus LGT-2 was cultured in potato-dextrose broth (PDB) for 20d at 28 °C on a 50 L fermenter. The fermentation broth was filtered (0 mg). Fr. 5 was purified by semipreparative HPLC (MeOH–H₂O, 40:60) to yield compound 5 (5.6 mg), 6 (6.5 mg), 9 (8.5 mg).

Antimicrobial assay: The antimicrobial assay was performed by measuring zones of inhibition (mm) using standard disc diffusion technique (3). A positive control, amoxicillin (0.1mg/mL) was used for comparison purpose, whilst a blank disc impregnated with appropriate solvent was used as a negative control. In addition, the minimum inhibitory concentrations (MIC) of all the monomer compounds against *Escherichia coli*, *Pseudomonas Aeruginosa*, *Staphylococcus aureus*, *Bnfillus licheniformis*, *Streptococcus pneumoniae*, were determined by serial dilution technique.

Cytotoxicity Bioassay: The cytotoxicity of compounds 1-11 against B16 cancer cell line was measured by the MTT method(4). Cyclophosphamide was used as positive control.

Anti-MAO and anti-AChE Bioassay: The

procedure of testing MAO and AChE inhibiting activity was same with that reported in our previous paper (5, 6).

Results and Discussion

This study was focused on compounds isolated from second metabolites of *Talaromyces sp.* LGT-2, and evaluated biological activities. The methods of Column Chromatography and HPLC Chromatograph were simple and rapid for separation and purification of natural compounds. In the present study, eleven compounds (1-11) including nine alkaloids (1-9), one triterpenoid saponin (10) and one formamide (11) were isolated from *Talaromyces sp.* LGT-2. This is the first report of the isolation of alkaloids (1-9) from *Talaromyces* genus. Compound 11 showed moderate anti-monoamine oxidase activity with IC₅₀ value of 61µM, therefore, it was proved to be the responsible compound of anti-MAO activity; compounds 3, 4, 8 showed weaker anti-acetylcholinesterase activity; compounds 1, 3, 4, 7, 8, 9 showed moderate antibacterial activity (Table 1.); compounds 7, 8, 9 showed weak cytotoxicity against B16 cancer cell line with inhibitory rate of 86%, 82%, 78%, respectively, at the concentration of 500 µg/mL.

Structure elucidation of the isolated compounds:

Fumitremorgin C (1). Colorless amorphous powder. EI-MS *m/z* (%): 379 (80) [M]⁺, 364 (14) [M-CH₃]⁺, 324 (32), 281 (100), 212 (67). ¹H-NMR (400, CDCl₃, δ, ppm, *J*/Hz): 7.81 (1H, s, H-1), 7.43 (1H, d, *J* = 8.0, H-16), 6.86 (1H, s, H-19), 6.80 (1H, d, *J* = 8.0, H-17), 5.98 (1H, d, *J* = 9.2, H-3), 4.90 (1H, d, *J* = 9.2, H-21), 4.18 (1H, dd, *J* = 11.6, 4.8, H-12), 4.11 (1H, t, *J* = 8.0, H-6), 3.83




Figure 1. The structures of compounds 1-11

(3H, s, OMe), 3.64 (2H, m, H-9), 3.50 (1H, dd, $J = 16.0, 4.8$, H-13a), 3.09 (1H, dd, $J = 16.0, 11.6$, H-13b), 2.38 (1H, m, H-7a), 2.25 (1H, m, H-7b), 2.06 (1H, m, H-8a), 1.99 (3H, s, H-24), 1.89 (1H, m, H-8b), 1.68 (3H, s, H-23); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3 , δ , ppm): 169.5 (C-5), 165.7 (C-11), 156.6 (C-18), 137.0 (C-20), 133.9 (C-22), 132.2 (C-2), 124.2 (C-21), 120.7 (C-15), 118.8 (C-16), 109.5 (C-17), 106.3 (C-14), 95.3 (C-19), 59.2 (C-6), 56.8 (C-12), 55.7 (OMe), 51.0 (C-3), 45.4 (C-9), 28.6 (C-7), 25.7 (C-23), 23.0 (C-8), 21.9 (C-13), 18.1 (C-24)^[7].

Brevianamide F (2). White amorphous powder. EI-MS m/z (%): 283 (10) $[\text{M}]^+$, 185 (8), 130 (100), 84 (20), 43 (17). $^1\text{H-NMR}$ (400 MHz, CDCl_3 , δ , ppm, J/Hz): 8.61 (1H, s, -NH), 7.58 (1H, d, $J = 8.0$, H-7), 7.38 (1H, d, $J = 8.0$, H-4), 7.24 (1H, t, $J = 8.0$, H-6), 7.14 (1H, t, $J = 8.0$, H-5), 7.05 (1H, s, H-2), 5.86 (1H, s, -NH), 4.36 (1H, d, $J = 9.2$, H-9), 4.06 (1H, t, $J = 8.0$, H-12), 3.76 (1H, dd, $J = 1.2, 14.4$, H-8b), 3.63 (2H, m, H-15), 2.97 (1H, dd, $J = 9.2, 14.4$, H-8a), 1.86-2.34 (4H, m, H-16, 17); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3 , δ , ppm): 169.4 (C-11), 165.5 (C-14), 136.6 (C-7a), 126.6 (C-3a), 123.4 (C-2), 122.7 (C-5), 119.7 (C-6), 118.5 (C-4), 111.5 (C-7), 109.5 (C-3), 59.1 (C-12), 54.5 (C-9), 45.3 (C-15), 28.2 (C-17), 26.8 (C-8), 22.5 (C-16)(8).

Pseurotin A₁ (3). Light yellow oil. $[\alpha]_{\text{D}}^{25} -4.8$ (c 0.1, MeOH). ESI-MS m/z 454.1 $[\text{M} + \text{Na}]^+$. $^1\text{H-NMR}$ (400 MHz, DMSO-d_6 , δ , ppm, J/Hz): 9.94 (1H, s, NH), 8.10 (2H, d, $J = 8.0$ Hz, H-19,

23), 7.63 (1H, t, $J = 7.3$, H-21), 7.52 (2H, t, $J = 8.0$, H-20, 22), 6.07 (1H, d, $J = 6.2$, 9-OH), 5.75 (1H, d, $J = 5.5$, 10-OH), 5.42 (1H, dd, $J = 7.0$, 11.0, H-13), 5.39 (1H, dd, $J = 8.1, 11.0$, H-12), 4.96 (1H, d, $J = 5.1$, 11-OH), 4.62 (1H, d, $J = 6.2$, H-9), 4.45 (1H, dd, $J = 5.2$, 11.0, H-11), 4.36 (1H, t, $J = 5.2$, H-10), 3.12 (3H, s, OMe-8), 2.01 (1H, m, H-14), 1.95 (1H, m, H-14), 1.66 (3H, s, H-16), 0.86 (3H, t, $J = 7.2$, H-15); $^{13}\text{C-NMR}$ (100 MHz, DMSO-d_6 , δ , ppm): 201.4 (C-4), 194.6 (C-17), 187.2 (C-2), 168.1 (C-6), 135.8 (C-13), 134.6 (C-18), 133.9 (C-21), 130.5 (C-19), 130.5 (C-23), 129.4 (C-12), 128.1 (C-20), 128.1 (C-22), 113.1 (C-3), 97.6 (C-8), 89.5 (C-5), 77.0 (C-9), 72.7 (C-10), 69.9 (C-11), 52.1 (OMe-8), 22.3 (C-14), 14.4 (C-15), 5.8 (C-16)(9).

Pseurotin A₂ (4). Light yellow oil. $[\alpha]_{\text{D}}^{25} -30.0$ (c 0.1, MeOH). ESI-MS m/z 454.1 $[\text{M} + \text{Na}]^+$. $^1\text{H-NMR}$ (400 MHz, DMSO-d_6 , δ , ppm, J/Hz): 9.98 (1H, s, NH), 8.28 (2H, d, $J = 8.0$, H-19, 23), 7.69 (1H, t, $J = 7.3$, H-21), 7.55 (2H, t, $J = 8.0$, H-20, 22), 6.36 (1H, d, $J = 10.0$, 9-OH), 5.88 (1H, d, $J = 5.5$, 10-OH), 5.47 (1H, dt, $J = 7.0$, 11.0, H-13), 5.41 (1H, dd, $J = 8.1, 11.0$, H-12), 5.10 (1H, d, $J = 5.1$, 11-OH), 4.18 (1H, d, $J = 10.0$, H-9), 4.57 (1H, dd, $J = 5.2, 8.1$, H-11), 4.51 (1H, t, $J = 5.2$, H-10), 3.21 (3H, s, OMe-8), 2.07 (2H, m, H-14), 1.66 (3H, s, H-16), 0.93 (3H, t, $J = 7.2$, H-15); $^{13}\text{C-NMR}$ (100 MHz, DMSO-d_6 , δ , ppm): 199.8 (C-4), 196.1 (C-17), 188.8 (C-2), 169.2 (C-6), 135.7 (C-13), 134.6 (C-18), 133.9 (C-21), 130.5 (C-19), 130.5 (C-23), 129.4 (C-

12), 128.1 (C-20), 128.1 (C-22), 114.0 (C-3), 95.4 (C-8), 88.0 (C-5), 75.8 (C-9), 71.9 (C-10), 69.6 (C-11), 51.7 (OMe-8), 21.7 (C-14), 14.4 (C-15), 5.8 (C-16)^[9].

Spirotryprostatin A (5). Colorless acicular crystals. ESI-MS m/z 396.0 $[M+H]^+$. ¹H-NMR (400 MHz, CDCl₃, δ , ppm, J /Hz): 7.51 (1H, s, H-1), 6.93 (1H, d, J = 8.4, H-4), 6.50 (1H, d, J = 8.4, H-5), 6.43 (1H, s, H-7), 5.00 (2H, m, H-18, 9), 4.77 (1H, J = 9.0, H-19), 4.29 (1H, t, J = 8.4, H-12), 3.80 (3H, s, -OMe), 3.68 (2H, m, H-15), 2.60 (1H, dd, J = 10.8, 13.2, H-13b), 1.95-2.41 (7H, m, H-13a, 14, 15, 8), 1.59 (3H, s, H-21), 1.25 (3H, s, H-22)(10).

6-Methoxyspirotryprostatin B (6). Colorless acicular crystals. ESI-MS m/z 392.2 $[M-H]^-$. ¹H-NMR (400 MHz, CDCl₃, δ , ppm, J /Hz): 7.64 (1H, s, H-1), 6.95 (1H, d, J = 8.4, H-4), 6.51 (1H, d, J = 8.4, H-5), 6.44 (1H, s, H-7), 5.76 (1H, s, H-8), 5.38 (1H, d, J = 8.8, H-18), 5.19 (1H, d, J = 8.8, H-19), 4.34 (1H, dd, J = 10.0, 6.0, H-12), 3.80 (3H, s, -OMe), 3.83 (1H, m, H-15b), 3.55 (1H, m, H-15a), 2.48 (1H, m, H-13b), 2.12 (1H, m, H-14b), 1.98 (2H, m, H-13a, 14a), 1.59 (3H, s, H-21), 1.25 (3H, s, H-22)(11).

3-Dehydroxymethylbisdethio-3, 10a-bis(methylthio)gliotoxin(7). Colorless acicular crystals. ESI-MS m/z 349.0 $[M + Na]^+$. ¹H-NMR (400 MHz, CD₃COCD₃, δ , ppm, J /Hz): 2.17 (3H, s, -SMe), 2.43 (3H, s, -SMe), 2.86 (2H, brs, H-10), 3.11 (3H, s, -NMe), 4.71 (1H, d, J = 13.2, H-5a), 4.81 (1H, m, H-6), 5.63 (1H, m, H-7), 5.89 (1H, m, H-8), 5.99 (1H, brs, H-9); ¹³C-NMR (100 MHz, CD₃COCD₃, δ , ppm): 168.7 (C-1), 165.0 (C-4), 133.9 (C-9a), 131.2 (C-8), 123.8 (C-7), 120.2 (C-9), 75.0 (C-6), (C-9a) 72.8 (C-11), 70.0 (C-5a), 68.1 (C-3), 38.8 (C-10), 31.9 (-NMe), 17.7 (-SMe), 14.6 (-SMe) (12).

Bisdethiobis(methylthio)gliotoxin(8). Light yellow oil. EI-MS m/z (%): 356 (10) $[M]^+$, 309 (50) $[M-SMe]^+$, 261 (100), 231 (75). ¹H-NMR (400 MHz, CD₃OD, δ , ppm, J /Hz): 2.24 (3H, s, -SMe), 2.27(3H, s, -SMe), 2.93 (1H, d, J = 14.6, H-10a), 3.12 (1H, d, J = 14.6, H-10b), 3.11 (3H, s, -NMe), 3.86 (1H, d, J = 11.6, H-15a), 4.24 (1H, d, J = 11.6, H-15b), 4.86 (1H, m, H-5a), 4.95 (1H, m, H-6), 5.67(1H, m, H-7), 5.92(2H, m, H-8, 9); ¹³C-NMR (100 MHz, CD₃OD, δ , ppm): 168.3 (C-1), 167.7 (C-4), 134.0 (C-9a),

130.7 (C-8), 124.8 (C-7), 120.8 (C-9), 75.7 (C-6), 74.3 (C-3), 73.1 (C-11), 70.4 (C-5a), 64.6 (C-15), 39.7 (C-10), 29.1 (-NMe), 15.2 (-SMe), 13.6 (-SMe) (13). Didehydrobisdethiobis(methylthio)gliotoxin (9). Light yellow oil. EI-MS m/z (%): 354 (9) $[M]^+$, 307 (79) $[M-SCH_3]^+$, 259 (100), 243 (41), 229 (88), 160 (58). ¹H-NMR (400 MHz, CDCl₃, δ , ppm, J /Hz): 10.20 (1H, s, -OH), 7.16 (1H, t, J = 8.0, H-8), 6.89 (1H, d, J = 8.0, H-9), 6.81 (1H, d, J = 8.0, H-7), 4.52 (1H, d, J = 12.0, H-15b), 3.98 (1H, d, J = 12.0, H-15a), 3.60 (1H, d, J = 12.6, H-10b), 3.46 (1H, d, J = 12.6, H-10a), 3.21 (3H, s, -NMe), 2.33 (3H, s, -SMe), 2.25 (3H, s, -SMe)(14).

Cyclosieversioside F (10). Colorless amorphous powder. ¹H-NMR (400 MHz, CD₃OD, δ , ppm, J /Hz): 4.90 (1H, d, J = 7.6, H-1 of D-glucose), 4.65 (1H, d, J = 7.6, H-1 of D-xylose), 4.29 (1H, m, H-16), 3.13-3.85 (11H, m, D-xylose + D-glucose), 1.00, 1.01, 1.12, 1.20, 1.25, 1.25, 1.27 (each 3H, s, Me-18, 21, 26, 27, 28, 29, 30), 0.27 and 0.58 (each 1H, d, J = 4.0, H-19); ¹³C-NMR (100 MHz, CD₃OD, δ , ppm): 107.4 (C-1', Xyl), 104.9 (C-1'', Glu), 90.0 (C-20), 88.4 (C-3), 82.5 (C-24), 80.0 (C-6), 78.6 (C-3'', Glu), 77.7 (C-5'', Glu), 75.6 (C-2'', Glu), 75.5 (C-2', Xyl), 74.7 (C-3', Xyl), 74.7 (C-16), 71.8 (C-4', Xyl), 71.3 (C-4'', Glu), 71.3 (C-25), 66.7 (C-5', Xyl), 62.9 (C-6'', Glu), 58.9 (C-17), 53.3 (C-5), 46.7 (C-13), 47.0 (C-14), 46.7 (C-8), 46.1 (C-15), 43.1 (C-4), 35.4 (C-7), 35.1 (C-22), 34.2 (C-12), 33.0 (C-1), 30.4 (C-2), 29.6 (C-19), 28.2 (C-26), 29.6 (C-10), 28.5 (C-27), 27.0 (C-29), 27.6 (C-21), 26.5 (C-11), 26.8 (C-23), 22.1 (C-9), 21.5 (C-28), 20.2 (C-18), 16.6 (C-30)(15).

(Z)-N-(4-hydroxystyryl)formamide(11). Colorless acicular crystals. ESI-MS m/z 162.0 $[M-H]^+$. ¹H-NMR (CD₃OD, 400 MHz, δ , ppm, J /Hz): 8.08 (1H, s, -CHO), 7.17 (2H, d, J = 8.0, H-2, H-6), 6.75 (1H, d, J = 9.6, H-7), 6.73 (2H, d, J = 8.0, H-3, H-5), 5.73 (1H, d, J = 9.6, H-8). ¹³C-NMR (100 MHz, CD₃OD, δ , ppm): 118.0(C-1), 111.1(C-2), 126.8 (C-1'), 130.2 (C-2' /6'), 116.2(C-3'/5'), 157.0 (C-4'), 160.7 (-CHO) (16).

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No.

21262022) and the Elitist Teachers Program of Lanzhou University of Technology (No. J201303).

References

- (1) Sun C, Wang JW, Fang L, Gao XD and Tan RX. Free radical scavenging and antioxidant activities of EPS2, an exopolysaccharide produced by a marine filamentous fungus *Keissleriella* sp. YS 4108. *Life Sciences* (2004) 75: 1063-73.
- (2) Zhang HW, Song YC and Tan RX. Biology and chemistry of endophytes. *Nat. Prod. Rep.* (2006) 23: 753-771.
- (3) Vital PG and Rivera WL. Antimicrobial activity and cytotoxicity of *chromolaena odorata* (L. f.) King and Robinson and *Uncaria perrottetii* (A. Rich) Merr. extracts. *J. Med. Plants Res.* (2009) 3: 511-8.
- (4) Wang YN, Wu W, Chen HC and Fang H. Genistein protects against UVB-induced senescence-like characteristics in human dermal fibroblast by p66Shc down-regulation. *J. Dermatol. Sci.* (2010) 58: 19-27.
- (5) Yang ZD, Ren J and Shu ZM. Monoamine oxidase inhibitory activity of the total alkaloid and organic acid from Chinese herbal medicines. *Adv. Mater. Res.* (2013) 781-784: 899-902.
- (6) Yang ZD, Duan DZ, Xue WW, Yao XJ and Li S. Steroidal alkaloids from *Holarrhena antidysenterica* as acetylcholinesterase inhibitors and the investigation for structure-activity relationships. *Life Sciences* (2012) 90: 929-933.
- (7) Ren H, Cao XL, Wang QE and Xu CM. Antitumor metabolites from fungus *Aspergillus sydowi* D2-6. *Chin. Pharm. J.* (2011) 46: 569-575.
- (8) Kobayashi M, Aoki S, Gato K, Matsunami K, Kurosu M and Kitagawa I. Marine natural products. 34. trisindoline, a new antibiotic indole trimer, produced by a bacterium of *Vibrio* sp. separated from the marine sponge *Hyrtios-altum*. *Chem. Pharm. Bull.* (1994) 42: 2449-2551.
- (9) Wang FZ, Li DH, Zhu TJ, Zhang M and Gu QQ. Pseurotin A₁ and A₂, two new 1-oxa-7-azaspiro[4.4]non-2-ene-4,6-diones from the holothurian-derived fungus *Aspergillus fumigatus* WFZ-25. *Can. J. Chem.* (2011) 89: 72-6.
- (10) Onishi T, Sebahar PR and Williams RM. Concise, asymmetric total synthesis of spirotryprostatin A. *Organic Letters* (2003) 5: 3135-7.
- (11) Zhang M, Wang WL, Fang YC, Zhu TJ, Gu QQ and Zhu WM. Cytotoxic alkaloids and antibiotic nordammarane triterpenoids from the marine-derived fungus *Aspergillus sydowi*. *J. Nat. Prod.* (2008) 71: 985-9.
- (12) Okamoto M, Yoshida K, Uchida I, Nishikawa M, Kohsaka M and Aoki H. Studies of platelet activating factor (PAF) antagonists from microbial products. I. Bisdethiobis(methylthio)gliotoxin and its derivatives. *Chem. Pharm. Bull.* (1986) 34: 340-4.
- (13) Afiyatullo ShSh, Kalinovskii AI, Pivkin MV, Dmitrenok PS and Kuznetsova TA. Alkaloids from the marine isolate of the fungus *Aspergillus fumigatus*. *Chem. Nat. Compd.* (2005) 41: 236-8.
- (14) Zhang LM, Li ZL, Bai J, Wu X, Wang Y and Hua HM. Metabolites of *Aspergillus* sp. HT-2. *Chin. Pharm. J.* (2011) 46: 1154-8.
- (15) Iskenderov DA, Keneshov BM and Isaev MI. Triterpene glycosides from *Astragalus* and their genins. LXXXVI. Glycosides from *A. sieversianus*. *Chem. Nat. Compd.* (2008) 44: 319-323.
- (16) Qu P, Liu PP, Fu P, Wang Y and Zhu WM. Secondary metabolites of halotolerant fungus *penicillium chrysogenum* HK14-01 from the Yellow River Delta area. *Acta Microbiologica Sinica.* (2012) 52: 1103-12.

This article is available online at <http://www.ijpr.ir>

**Search full text articles?
Visit <http://www.ijpr.ir>
or
[http:// ijpr.sbm.ac.ir](http://ijpr.sbm.ac.ir)**